First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
| Image |  |
|---|---|
| Description | scientific article published in June 2023 |
| Author/s |
author: Rachel N. Grisham |
| Publication date | June 1, 2023 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |